A critic of the pharmaceutical industry, Avorn believes companies are now somewhat more cautious, primarily because the FDA has become more vigilant.
- Link to Article
- Article source:
- About
-
SUPPORT OPEN-MINDED DEBATE
Help us bring debate to communities and classrooms across the nation.
Donate
-
- Header Bottom
